Kyogoku unyu shoji
9073
BlueMeme
4069
Estore
4304
Visumo
303A
D. Western Therapeutics Institute
4576
(Q1)Jun 30, 2024 | (FY)Mar 31, 2024 | (Q4)Mar 31, 2024 | (Q3)Dec 31, 2023 | (Q2)Sep 30, 2023 | (Q1)Jun 30, 2023 | (FY)Mar 31, 2023 | (Q4)Mar 31, 2023 | (Q3)Dec 31, 2022 | (Q2)Sep 30, 2022 | |
---|---|---|---|---|---|---|---|---|---|---|
Total revenue | 1.96%76.75B | 1.40%324.77B | -1.13%83.6B | -1.09%84.52B | 5.55%81.38B | 2.87%75.28B | 6.99%320.28B | -3.23%84.55B | 8.47%85.46B | 12.97%77.1B |
Cost of revenue | -0.17%63.5B | -0.10%270.42B | -3.05%68.9B | -3.90%69.99B | 4.97%67.92B | 2.45%63.6B | 7.24%270.69B | -4.36%71.07B | 9.69%72.83B | 12.94%64.7B |
Gross profit | 13.50%13.25B | 9.60%54.36B | 9.02%14.69B | 15.09%14.53B | 8.58%13.46B | 5.20%11.68B | 5.68%49.59B | 3.17%13.48B | 1.94%12.62B | 13.11%12.39B |
Operating expense | -0.58%6.84B | 1.79%28.42B | 3.92%7.34B | -0.32%7.11B | 2.64%7.08B | 0.92%6.88B | 6.58%27.92B | 1.49%7.06B | 9.78%7.14B | 8.06%6.9B |
Operating profit | 33.73%6.41B | 19.67%25.94B | 14.63%7.36B | 35.13%7.42B | 16.06%6.38B | 12.02%4.79B | 4.54%21.68B | 5.08%6.42B | -6.73%5.49B | 20.17%5.49B |
Net non-operating interest income (expenses) | -2.56%-40M | 627.27%400M | 285.00%539M | -36.11%-49M | -50.00%-51M | -160.00%-39M | 161.80%55M | 551.61%140M | -111.76%-36M | -54.55%-34M |
Non-operating interest income | ---- | 236.93%593M | ---- | ---- | ---- | ---- | --176M | ---- | ---- | ---- |
Non-operating interest expense | 2.56%40M | 59.50%193M | 50.00%54M | 36.11%49M | 50.00%51M | 160.00%39M | 35.96%121M | 16.13%36M | 111.76%36M | 54.55%34M |
Net investment income | -56.93%435M | 94.69%1.5B | 1,080.00%413M | 48.21%-362M | 3.27%442M | 0.20%1.01B | -16.36%772M | -91.14%35M | -407.93%-699M | 441.77%428M |
Gain(Loss) on financial instruments designated as cash flow hedges | ||||||||||
Gain(Loss) on derecognition of available-for-sale financial assets | 16M | 3,420.00%176M | 13M | 162M | 5M | 0 | ||||
Income from associates and other participating interests | 30.50%445M | 14.62%1.14B | -26.08%292M | 62.11%261M | 21.50%243M | 44.49%341M | 992M | 419.74%395M | 136.59%161M | 70.94%200M |
Special income (charges) | 105.56%1M | -12.15%-600M | -188.66%-560M | 99.12%-3M | -171.43%-19M | -357.14%-18M | 48.01%-535M | 60.00%-194M | 37.20%-341M | -177.78%-7M |
Less:Impairment of capital assets | ---- | 12.37%109M | ---- | ---- | ---- | ---- | --97M | ---- | ---- | ---- |
Less:Other special charges | -105.56%-1M | -104.06%-16M | -205.66%-56M | --3M | --19M | 357.14%18M | -45.13%394M | -69.54%53M | ---- | ---- |
Less:Write off | ---- | 1,052.27%507M | ---- | ---- | ---- | ---- | -85.85%44M | ---- | ---- | ---- |
Other non-operating income (expenses) | -29.80%212M | -10.61%851M | -227.27%-224M | 83.04%421M | -19.27%352M | 174.55%302M | -15.00%952M | -1.12%176M | -12.88%230M | 10.38%436M |
Income before tax | 17.01%7.48B | 22.96%29.41B | 12.33%7.83B | 63.28%7.85B | 12.64%7.34B | 13.64%6.39B | 10.42%23.91B | 11.65%6.97B | -10.54%4.81B | 26.64%6.52B |
Income tax | 12.64%2.26B | 27.73%9.09B | 38.80%2.57B | 60.93%2.28B | 8.34%2.24B | 12.35%2.01B | 4.25%7.12B | -13.28%1.85B | -23.43%1.42B | 34.05%2.06B |
Net income | 19.02%5.21B | 20.94%20.31B | 2.77%5.26B | 64.30%5.57B | 14.59%5.11B | 14.27%4.38B | 13.26%16.8B | 24.57%5.12B | -3.78%3.39B | 23.47%4.46B |
Net income continuous operations | 19.02%5.21B | 20.94%20.31B | 2.77%5.26B | 64.26%5.57B | 14.64%5.11B | 14.24%4.38B | 13.26%16.8B | 24.57%5.12B | -3.75%3.39B | 23.48%4.46B |
Noncontrolling interests | 10.23%517M | 11.08%2.15B | 3.02%614M | 37.87%659M | -23.24%403M | 41.27%469M | 10.22%1.93B | 45.72%596M | -10.65%478M | 38.52%525M |
Net income attributable to the company | 20.05%4.69B | 22.22%18.17B | 2.74%4.65B | 68.59%4.91B | 19.67%4.7B | 11.71%3.91B | 13.67%14.86B | 22.24%4.52B | -2.51%2.91B | 21.71%3.93B |
Preferred stock dividends | ||||||||||
Other under preferred stock dividend | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Net income attributable to common stockholders | 20.05%4.69B | 22.22%18.17B | 2.74%4.65B | 68.59%4.91B | 19.67%4.7B | 11.71%3.91B | 13.67%14.86B | 22.24%4.52B | -2.51%2.91B | 21.71%3.93B |
Gross dividend payment | ||||||||||
Basic earnings per share | 21.17%53.06 | 22.96%203.63 | 3.28%52.22 | 68.87%54.95 | 20.36%52.67 | 13.01%43.79 | 18.76%165.61 | 24.50%50.56 | 0.99%32.54 | 29.93%43.76 |
Diluted earnings per share | 21.15%53.04 | 22.96%203.55 | 3.26%52.19 | 68.94%54.94 | 20.35%52.64 | 13.01%43.78 | 18.75%165.54 | 24.48%50.54 | 0.96%32.52 | 29.95%43.74 |
Dividend per share | 0 | 37.50%55 | 31.82%29 | 0 | 44.44%26 | 0 | -51.22%40 | 22.22%22 | 0 | -71.88%18 |
Currency Unit | JPY | JPY | JPY | JPY | JPY | JPY | JPY | JPY | JPY | JPY |
Accounting Standards | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP |